EpiVax Oncology - EpiVax, Inc. - Informatics and Immunology

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Corey Iacono | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H

Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

by Riley Nolan | May 13, 2021

Immunoinformatic Analysis of Pancreatic Cancer Mutanomes: Impact of Regulatory T Cell Neo-Epitopes on Patient Outcome

Immunoinformatic Analysis of Pancreatic Cancer Mutanomes: Impact of Regulatory T Cell Neo-Epitopes on Patient Outcome

by Annie De Groot | May 14, 2019

EpiVax_Oncology_NYAS_08May19_35Wx25H

Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

by Annie De Groot | Apr 8, 2019

EpiVax_Oncology_TRI-CON_CT26_04Mar19_32w44h

From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

by Annie De Groot | Nov 6, 2018

EpiVax_Oncology_Ancer_SITC_05Nov18_39Wx35H

« Older Entries